Press Release FeedGet the RSS feed
Menu

Business Wire

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Business Wire

Eric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary Leadership

Bradley L. Campbell to be Appointed President and CEO Effective December 1, 2026

SAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company's Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and a member of the Board, effective December 1, 2026. Dr. Dube will continue to serve as president and chief executive officer until that date and will remain employed by the Company as executive advisor through February 15, 2027, to support an orderly transition.

"Leading Travere has been the greatest privilege of my career," said Dr. Dube. "When I became CEO almost eight years ago, I believed we had an opportunity and a responsibility to deliver meaningful innovation to rare disease communities that had waited far too long for better therapies. Together, our team has brought important medicines to patients, built a diverse pipeline and achieved a milestone particularly meaningful to me - the first approved medicine for FSGS. My own experiences with rare disease have also given me a profound appreciation for health, family and time. After considerable reflection, I've decided this is the right moment for me to step away from full-time operating roles and devote greater attention to those priorities. I have made that decision with enormous confidence in Travere's future, its leadership team and in Bradley. He has the unique experience, values and commitment to patients to lead this company through its next chapter, and I look forward to supporting a seamless transition."

Since becoming president and chief executive officer in January 2019, Dr. Dube has guided Travere's evolution into a leading rare disease company. Under his leadership, the Company achieved regulatory approvals in IgA nephropathy and focal segmental glomerulosclerosis (FSGS), expanded its pipeline and capabilities, and strengthened a culture grounded in patients, purpose and performance.

"Eric has led Travere through a period of extraordinary evolution, further establishing the Company as a leader in rare kidney disease and creating a strong foundation for continued growth and positive impact," said Gary Lyons, chairman of the Travere Board of Directors. "The Board has worked closely and collaboratively with Eric on succession planning and conducted a thoughtful and comprehensive search process focused on the experience and leadership qualities required for the Company's next chapter. The Board fully supports and respects Eric's personal decision, and we are deeply grateful for his leadership and his commitment to ensuring a seamless transition."

  1. HealthcareAV Laboratories Joins Regenivus (Mitrone Healthcare Ltd.) at Dublin’s Aesthetic & Regenerative Medicine ConferenceDUBLIN, October 18, 2026--AV Laboratories, a clinical skin longevity brand bridging advanced formulation science and skincare innovation, is pleased to announce its participation in The Aesthetic & Regenerative Medicine Conference, taking place on 18–19 October 2026 at Croke Park, Dublin. The brand wil
  2. FUJIFILM Integrated Inkjet SolutionsFujifilm Introduces FUJIFILM HX1024 Printbar SystemNew printbar brings full-color customizable on-demand digital printing to building products LEBANON, N.H., October 18, 2026--FUJIFILM Integrated Inkjet Solutions today announced the introduction of the FUJIFILM HX1024 Printbar System, designed to support customized printing using the company's advanced
  3. EnergyWorld’s First Commercial Ship-to-Ship Green Ammonia Bunkering Completed in Zhoushan, Zhejiang, ChinaZHOUSHAN, China, October 18, 2026--On October 13, 2026, the world's first commercial ship-to-ship bunkering of green ammonia fuel was completed at an anchorage in Zhoushan Port, Zhejiang Province, China. A total of 1,000 tonnes of green ammonia from the HyFlow-1 Songyuan Hydrogen Energy Industrial Park
  4. SaaSThe Prostate Cancer FoundationProstate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types – – New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges i
  5. FinanceAlign Technology, Inc.Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent CourtCompanies: Align TechnologySAN JOSE, Calif. & TEMPE, Ariz., October 17, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court ("UPC") finding that aligner syst
  6. AISyncra and Neumetry Partner to Build AI-Powered Readiness Platform for Teenage Athletes and Their CoachesSmart ring data meets FDA-cleared physiological AI to help coaches see which athletes are ready to compete, and which need rest LAS VEGAS & SAN JOSE, Calif., October 17, 2026--Syncra Labs Inc., maker of the Syncra smart ring, and Neumetry Medical, Inc., developer of an FDA-cleared predictive health pla